Biomarkers for lung cancer screening: Interpretation and implications of an early negative advanced validation study

American Journal of Respiratory and Critical Care Medicine

Volumn 179, Issue 1, 2009, Pages 1-2

  Hirschowitz, Edward A ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; K RAS PROTEIN; PROTEIN P53;

CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; COMPUTER ASSISTED TOMOGRAPHY; DISEASE MARKER; DNA DETERMINATION; EDITORIAL; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; PREVALENCE; PRIORITY JOURNAL; SOMATIC MUTATION;

DISEASE PROGRESSION; DNA, NEOPLASM; HUMANS; LUNG NEOPLASMS; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 58349088702     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200809-1395ED     Document Type: Editorial

References (11)

1. Sozzi G, Roz L, Conte D, Mariani L, Andriani F, Lo Vullo S, Verri C, Pastorino U. Plasma DNA quantification in lung cancer computed tomography screening: five-year results of a prospective study. Am J Respir Crit Care Med 2009;179:69-74.
2. Bremnes RM, Sirera R, Camps C. Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up? Lung Cancer 2005;49:1-12.
3. Ziegler A, Zangemeister-Wittke U, Stahel RA. Circulating DNA: a new diagnostic gold mine? Cancer Treat Rev 2002;28:255-271.
4. Gormally E, Caboux E, Vineis P, Hainaut P. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res 2007;635:105-117.
5. Sozzi G, Conte D, Leon M, Ciricione R, Roz L, Ratcliffe C, Roz E, Cirenei N, Bellomi M, Pelosi G, et al. Quantification of free circulating DNAas a diagnostic marker in lung cancer. J Clin Oncol 2003;21:3902-3908.
6. Gormally E, Hainaut P, Caboux E, Airoldi L, Autrup H, Malaveille C, Dunning A, Garte S, Matullo G, Overvad K, et al. Amount of DNA in plasmaandcancer risk: a prospective study. Int J Cancer 2004;111:746-749.
7. Gormally E, Vineis P, Matullo G, Veglia F, Caboux E, Le Roux E, Peluso M, Garte S, Guarrera S, Munnia A, et al. TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: a prospective study. Cancer Res 2006;66:6871-6876.
8. Bach PB, Jett JR, Pastorino U, Tockman MS, Swensen SJ, Begg CB. Computed tomography screening and lung cancer outcomes. JAMA 2007;297:953-961.
9. Sozzi G, Roz L, Conte D, Mariani L, Andriani F, Verderio P, Pastorino U. Effects of prolonged storage of whole plasma or isolated plasma DNA on the results of circulating DNA quantification assays. J Natl Cancer Inst 2005;97:1848-1850.
10. Bach PB. Is our natural-history model of lung cancer wrong? Lancet Oncol 2008;9:693-697.
11. Lindell RM, Hartman TE, Swensen SJ, Jett JR, Midthun DE, Tazelaar HD, Mandrekar JN. Five-year lung cancer screening experience: CT appearance, growth rate, location, and histologic features of 61 lung cancers. Radiology 2007;242:555-562.